BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Cancer Treat Rev. 2014;40:701-715. [PMID: 24731471 DOI: 10.1016/j.ctrv.2014.02.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Chung SY, Chen YH, Lin PR, Chao TC, Su JC, Shiau CW, Su Y. Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells. Cell Death Discov 2018;4:25. [PMID: 30109144 DOI: 10.1038/s41420-018-0084-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
2 Sartore-bianchi A, Loupakis F, Argilés G, Prager G. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology 2016;27:1456-66. [DOI: 10.1093/annonc/mdw191] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
3 Yoon SE, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST. The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. J Cancer 2019;10:1611-5. [PMID: 31205516 DOI: 10.7150/jca.29106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Malik M, Michalak M, Radecka B, Gełej M, Jackowska A, Filipczyk-Cisarż E, Hetman K, Foszczyńska-Kłoda M, Kania-Zembaczyńska B, Mańka D, Orlikowska M, Rogowska-Droś H, Bodnar L. Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil. J Clin Med 2021;10:5107. [PMID: 34768626 DOI: 10.3390/jcm10215107] [Reference Citation Analysis]
5 Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World J Gastroenterol 2016; 22(23): 5400-5405 [PMID: 27340356 DOI: 10.3748/wjg.v22.i23.5400] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
6 Jensen BV, Schou JV, Yilmaz M, Johannesen HH, Skougaard K, Linnemann D, Hogdall EV, Larsen FO, Johansen JS, Pfeiffer P, Nielsen DL. Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. Int J Cancer 2020. [PMID: 33336394 DOI: 10.1002/ijc.33448] [Reference Citation Analysis]
7 Zhang HY, Guo JH, Gao S, Chen H, Wang XD, Zhang PJ, Liu P, Cao G, Xu HF, Zhu LZ, Yang RJ, Li J, Zhu X. Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy. World J Gastrointest Oncol 2018; 10(11): 431-438 [PMID: 30487954 DOI: 10.4251/wjgo.v10.i11.431] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Ducreux M, Bennouna J, Adenis A, Conroy T, Lièvre A, Portales F, Jeanes J, Li L, Romano A. Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. Cancer Chemother Pharmacol 2017;79:9-16. [DOI: 10.1007/s00280-016-3193-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
9 Dong N, Meng F, Wu Y, Wang M, Cui Y, Zhang S. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer. Tumor Biol 2015;36:7691-8. [DOI: 10.1007/s13277-015-3492-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis. 2016;18:364-371. [PMID: 26400556 DOI: 10.1111/codi.13130] [Cited by in Crossref: 111] [Cited by in F6Publishing: 92] [Article Influence: 22.2] [Reference Citation Analysis]
11 Lee MS, Cho HJ, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Cho YB, Kim ST. Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. Ther Adv Med Oncol 2020;12:1758835920965842. [PMID: 33224274 DOI: 10.1177/1758835920965842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, Taieb J. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol 2018;29:835-56. [PMID: 29452346 DOI: 10.1093/annonc/mdy038] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
13 Yu Z, Huang R, Zhao L, Wang X, Shangguan X, Li W, Li M, Yin X, Zhang C, Liu D. Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study. Front Oncol 2021;11:757196. [PMID: 34745993 DOI: 10.3389/fonc.2021.757196] [Reference Citation Analysis]
14 Zaniboni A, Bertocchi P, Barni S, Petrelli F. TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review. Clinical Colorectal Cancer 2016;15:292-7. [DOI: 10.1016/j.clcc.2016.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Bayoglu İV, Yildiz I, Varol U, Cokmert S, Alacacıoğlu A, Kucukzeybek Y, Akyol M, Demir L, Dirican A, Tarhan O. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemp Oncol (Pozn) 2015;19:385-90. [PMID: 26793023 DOI: 10.5114/wo.2015.53374] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Jiang Q, Li Q, Chen H, Shen A, Cai Q, Lin J, Peng J. Scutellaria barbata D. Don inhibits growth and induces apoptosis by suppressing IL-6-inducible STAT3 pathway activation in human colorectal cancer cells. Exp Ther Med 2015;10:1602-8. [PMID: 26622533 DOI: 10.3892/etm.2015.2692] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
17 Wu DM, Wang YJ, Fan SH, Zhuang J, Zhang ZF, Shan Q, Han XR, Wen X, Li MQ, Hu B, Sun CH, Bao YX, Xiao HJ, Yang L, Lu J, Zheng YL. Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer. Oncotarget 2017;8:100668-77. [PMID: 29246011 DOI: 10.18632/oncotarget.22177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Christensen TD, Jensen SG, Larsen FO, Nielsen DL. Systematic review: Incidence, risk factors, survival and treatment of bone metastases from colorectal cancer. J Bone Oncol 2018;13:97-105. [PMID: 30591863 DOI: 10.1016/j.jbo.2018.09.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treat Rev 2019;73:41-53. [PMID: 30616224 DOI: 10.1016/j.ctrv.2018.12.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
20 Mashima T, Taneda Y, Jang MK, Mizutani A, Muramatsu Y, Yoshida H, Sato A, Tanaka N, Sugimoto Y, Seimiya H. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget 2017;8:47902-15. [PMID: 28615517 DOI: 10.18632/oncotarget.18146] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
21 Pereira ED, Cerruti R, Fernandes E, Peña L, Saez V, Pinto JC, Ramón JA, Oliveira GE, Souza Júnior FGD. Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin. Polímeros 2016;26:137-43. [DOI: 10.1590/0104-1428.2323] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
22 Bommer UA, Vine KL, Puri P, Engel M, Belfiore L, Fildes K, Batterham M, Lochhead A, Aghmesheh M. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun Signal 2017;15:9. [PMID: 28143584 DOI: 10.1186/s12964-017-0164-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
23 Zhang C, Xu Y, Wang H, Li G, Yan H, Fei Z, Xu Y, Li W. Curcumin reverses irinotecan resistance in colon cancer cell by regulation of epithelial-mesenchymal transition. Anticancer Drugs 2018;29:334-40. [PMID: 29420338 DOI: 10.1097/CAD.0000000000000599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
24 Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, Ruggieri L, Patelli G, Arena S, Bardelli A, Siena S, Sartore-Bianchi A. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev 2020;91:102112. [PMID: 33091698 DOI: 10.1016/j.ctrv.2020.102112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, Larsen FO, Nielsen DL. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review. Cancer Treat Rev 2018;62:61-73. [PMID: 29175677 DOI: 10.1016/j.ctrv.2017.10.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
26 Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H, Ishida H, Yamaguchi S, Kuramochi H, Fukazawa A, Sonoda H, Yoshimatsu K, Matsuda A, Hasegawa S, Sakamoto K, Otsuka T, Koda K; TAS CC3 Study Group. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int J Clin Oncol 2021;26:111-7. [PMID: 33083913 DOI: 10.1007/s10147-020-01794-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Haber Z, Lee EW, Price M, Wainberg Z, Hecht JR, Sayre J, Padia SA. Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study. Acad Radiol 2021:S1076-6332(21)00203-8. [PMID: 34099386 DOI: 10.1016/j.acra.2021.03.033] [Reference Citation Analysis]
28 Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell. 2016;29:587-601. [PMID: 27070705 DOI: 10.1016/j.ccell.2016.03.005] [Cited by in Crossref: 213] [Cited by in F6Publishing: 209] [Article Influence: 35.5] [Reference Citation Analysis]
29 Esposito D, Crescenzi E, Sagar V, Loreni F, Russo A, Russo G. Human rpL3 plays a crucial role in cell response to nucleolar stress induced by 5-FU and L-OHP. Oncotarget 2014;5:11737-51. [PMID: 25473889 DOI: 10.18632/oncotarget.2591] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
30 AlMusawi S, Ahmed M, Nateri AS. Understanding cell-cell communication and signaling in the colorectal cancer microenvironment. Clin Transl Med 2021;11:e308. [PMID: 33635003 DOI: 10.1002/ctm2.308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Keramida K, Farmakis D, López Fernández T, Lancellotti P. Focused echocardiography in cardio‐oncology. Echocardiography 2020;37:1149-58. [DOI: 10.1111/echo.14800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
32 Tarpgaard LS, Qvortrup C, Nielsen SL, Stenvang J, Detlefsen S, Brünner N, Pfeiffer P. New use for old drugs: Epirubicin in colorectal cancer. Acta Oncol 2021;60:954-6. [PMID: 33783307 DOI: 10.1080/0284186X.2021.1904519] [Reference Citation Analysis]
33 Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, Innominato P, Ajavon Y, Truant S, Castaing D, De Baere T, Kunstlinger F, Bouchahda M, Afshar M, Rougier P, Adam R, Ducreux M; Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International). Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol 2016;27:267-74. [PMID: 26578731 DOI: 10.1093/annonc/mdv548] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
34 Pfeiffer P, Yilmaz M, Möller S, Zitnjak D, Krogh M, Petersen LN, Poulsen LØ, Winther SB, Thomsen KG, Qvortrup C. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21:412-20. [PMID: 31999946 DOI: 10.1016/S1470-2045(19)30827-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 18.5] [Reference Citation Analysis]
35 Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, Schiavetto I, Bencardino K, Funaioli C, Ricotta R, Cipani T, Schirru M, Gambi V, Palmeri L, Carlo-Stella G, Rusconi F, Di Bella S, Burrafato G, Cassingena A, Valtorta E, Lauricella C, Pazzi F, Gambaro A, Ghezzi S, Marrapese G, Tarenzi E, Veronese S, Truini M, Vanzulli A, Siena S. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. Target Oncol 2017;12:525-33. [PMID: 28669023 DOI: 10.1007/s11523-017-0505-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
36 Sugiura K, Seo Y, Takahashi T, Tokura H, Ito Y, Tanaka M, Kishida N, Nishi Y, Onishi Y, Aoki H. Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer. BMC Gastroenterol 2021;21:184. [PMID: 33879100 DOI: 10.1186/s12876-021-01771-z] [Reference Citation Analysis]
37 Kim KR, Yoon JH, Shim HJ, Hwang JE, Bae WK, Chung IJ, Kim HN, Shin MH, Cho SH. Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer. Oncol Lett 2017;14:2491-8. [PMID: 28781687 DOI: 10.3892/ol.2017.6414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]